echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Kunyao Group valsartan and amlodipine tablets (Ⅰ) obtained the drug registration certificate

    Kunyao Group valsartan and amlodipine tablets (Ⅰ) obtained the drug registration certificate

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 15, Kunyao Group issued an announcement stating that the company had received the "Drug Registration Certificate" (certificate number: 2021S00974) for valsartan and amlodipine tablets (I) issued by the State Drug Administration


    Valsartan and Amlodipine Tablets (Ⅰ) are indicated for the treatment of essential hypertension and are used for monotherapy in patients who cannot adequately control blood pressure


    In addition to the original Novartis, the major global manufacturers of the drug include MYLAN, TEVA, etc.


    As of the date of this announcement, the company has invested approximately RMB 23.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.